Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-ranging study of JNJ-81241459 in moderate to severe plaque psoriasis
2023-508992-35-00Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of JNJ-1459 in plaque psoriasis (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: PASI 75 at Week 12. Started May 2024; status: completed.
02
Drugs
JNJ-1459
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2023-508992-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508992-35-00.